

On the Cutting Edge of Cancer Treatment



Charleston Veterinary Referral Center is proud to offer a new immunotherapy treatment for osteosarcoma from ELIAS Animal Health. This is a patented combination of vaccination and T cell infusion for the treatment of cancer in companion animals, with an initial focus on dogs with osteosarcoma.

Cancer Statistics

One in four dogs will develop cancer in their lifetime and cancer is the leading cause of death in dogs over the age of two. It's often discovered in late stages of the disease when treatment is difficult. Families of these pets are urgently looking for new and better options that not only prolong their companion's life, but also improve quality of life. ELIAS Animal Health is elevating the hope of veterinarians and pet owners by changing the way cancer is fundamentally treated. ELIAS Cancer Immunotherapy (ECI®), is their Autologous Prescription Product, harnessing the power of the dog's own immune system to eliminate the cancer.

How the OSA Vaccine Works

ELIAS Animal Health has developed a unique immunotherapy treatment protocol which may permit the dog's immune system to attack its own cancer cells. The ELIAS immunotherapy is an adoptive T cell therapy that fights cancer in two steps. First a vaccination series 'trains' the patient's T cells to recognize the cancer. Then, T cells are safely obtained from the patient through apheresis and activated to produce a large population of killer T cells that are reinfused into the patient to attack the cancer. ELIAS' cancer immunotherapy has demonstrated effectiveness in clinical trials in both canines and humans, while avoiding or minimizing the need for chemotherapy or radiation treatment.


ECI® Candidate Criteria

Dogs of any breed, age, or sex may be a candidate for this treatment if he/she meets the following criteria:

- 1. Newly diagnosed with appendicular osteosarcoma with the limb still in place (bone cancer in a limb, not skull or spine)¹
- 2. Under the care of a veterinarian who has assessed the patient to be in sufficiently good health overall to undergo and complete the 6-8 week treatment schedule
- 3. Is not currently pregnant or lactating
- 4. Has not previously received any treatments for its cancer
- 5. Does not have metastatic disease (spread of cancer) at the time of diagnosis
- 6. Is not currently on immunosuppressive drugs like prednisone or oclacitinib (a "washout" period prior to therapy may be needed for certain drugs)
- 7. Does not have a second malignancy (cancer of a different type)
- 8. Owner/guardian is able to take the dog to 6-10 scheduled clinic visits during the 6-8 week treatment schedule

Continued...

¹As a potential platform technology, the company continues to evaluate the use of ECI® for other cancer indications. ECI® is distributed as an experimental product under USDA 9 CFR 103.3. For use under supervision/prescription of a licensed veterinarian. Efficacy and safety have not been established.



Treatment Overview:

The treatment process averages 6-8 weeks for most patients.

- Tissue samples are acquired at the time of surgery (at CVRC), and the vaccine will be created in partnership with ELIAS.
- The patient will have multiple visits to CVRC for vaccines and associated therapy, as well as a visit to NC State University for collection of T-cells during the treatment period.

For More Information

If you would like more information, please contact our Oncology Coordinator, Amanda, at (843) 614-8387.



24/7/365 Emergency & Critical Care Comprehensive Specialty Care





CharlestonVRC | charlestonvrc.com | **843.614.8387** | 3484 Shelby Ray Court, Charleston, SC 29414